Keyphrases
Clinical Trials
79%
Olaparib
47%
Core Outcome Set
47%
Risk-benefit
32%
Patient Outcomes
26%
Objective Response Rate
26%
Risk Outcomes
23%
Selinexor
23%
Solid Malignancies
23%
Patient Benefit
23%
Drug Development
23%
Patient Risk
23%
Lung Cancer
23%
Reporting Guidelines
23%
Chronic Kidney Disease
23%
Web-based Survey
23%
Clinical Neurology
23%
Clinical Perspective
23%
Clinical Trial Registry
19%
Adverse Events
17%
Overall Survival
17%
Progression-free Survival
14%
Control Arm
14%
New Indication
11%
Drug Manufacturer
11%
Ovarian Cancer
11%
Health Research
11%
Trial Characteristics
10%
PubMed
8%
Median Progression-free Survival
8%
Cochrane
8%
Embase
8%
MEDLINE
8%
Requirements Selection
7%
Consolidated Standards of Reporting Trials (CONSORT)
7%
Top 100
7%
Cancer Clinical Trials
7%
Capital Investment
5%
Time Investment
5%
Pooled Analysis
5%
Mutation Characteristics
5%
Therapy Options
5%
Safety Criteria
5%
Novel Chemotherapy
5%
Drug Efficacy
5%
Adverse Event Rates
5%
Oncologic
5%
Solid Cancer
5%
Oncology
5%
Complete Response
5%
Medicine and Dentistry
Clinical Trial
100%
Olaparib
47%
Lung Cancer
47%
Clinical Neurology
23%
Chronic Kidney Disease
23%
Cross Sectional Study
23%
Malignant Neoplasm
20%
Clinician
15%
Ovarian Cancer
11%
Adverse Event
11%
Progression Free Survival
11%
Medicine
9%
Outcome Assessment
8%
Overall Survival
8%
Randomized Controlled Trial
7%
Pooled Analysis
5%
Prevalence
5%
Cancer Research
5%
Drug Therapy
5%
Oncology
5%
Drug Efficacy
5%
Lifespan
5%
Solid Malignant Neoplasm
5%
Chemotherapy
5%
Quality of Life
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
88%
Olaparib
47%
Lung Cancer
23%
Chronic Kidney Failure
23%
Drug Development
23%
Selinexor
23%
Adverse Event
23%
Progression Free Survival
23%
Malignant Neoplasm
17%
Overall Survival
17%
Ovary Cancer
11%
Pharmaceutical Manufacturing
11%
Prevalence
5%
Multiple Myeloma
5%
Chemotherapy
5%
Solid Malignant Neoplasm
5%
